Form 4: EyePoint Pharmaceuticals CEO Transfers Shares to Family Trust for Estate Planning

EyePoint Pharmaceuticals, Inc. President and CEO Jay S. Duker has disclosed the transfer of 56,665 shares of common stock to a family trust as part of a pre-planned transaction.

Summary

• Jay S. Duker, President and CEO of EyePoint Pharmaceuticals, Inc. (EYPT), reported a transaction involving 56,665 shares of common stock.
• The transaction, dated June 23, 2025, involved the sale of these shares to the Duker Family 2024 Irrevocable Trust.
• The shares were sold at a price of $8.21 per share, determined by the average of the high and low trading prices on the sale date.
• In exchange for the shares, the reporting person received a promissory note with a principal amount of $465,219.65.
• The transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
• The shares held in the Family Trust are for the benefit of Mr. Duker's children, and his spouse serves as a trustee.
• Mr. Duker disclaims beneficial ownership of the securities held by the Family Trust.
• Following this transaction, Mr. Duker directly beneficially owns 986 shares of common stock and indirectly owns 99,165 shares through the Family Trust.

Sentiment

Score: 5

Explanation: The document is a routine SEC Form 4 filing disclosing an insider transaction for estate planning purposes, which has a neutral impact on the company's operational or financial outlook.

Positives

• The transaction represents a structured estate planning move by the CEO, which can be viewed as a positive for the individual's personal financial management.

Future Outlook

The document, an SEC Form 4, is a disclosure of an insider transaction and does not provide any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• "The reporting person disclaims beneficial ownership of the security and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."

Industry Context

This Form 4 filing details a personal financial transaction by a company executive, specifically a transfer of shares to a family trust. Such transactions are common for estate planning purposes and typically do not reflect broader industry trends or competitive dynamics.

Related Party Transactions

• The transfer of 56,665 shares of common stock by Jay S. Duker to the Duker Family 2024 Irrevocable Trust, where the shares are for the benefit of his children and his spouse is a trustee, constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The transaction is a personal financial planning move by the CEO and is unlikely to have a direct material impact on the company's operations or share price. It provides transparency into insider holdings.
• Employees, Customers, Suppliers, Creditors: No direct impact is expected on these stakeholders as the transaction is a personal financial matter of an executive.

Key Dates

Keywords

EyePoint Pharmaceuticals, EYPT, Jay S. Duker, Form 4, Insider Transaction, Stock Transfer, Family Trust, Beneficial Ownership, CEO, Director, Rule 10b5-1(c)